Search Results - "Koski, Sheryl L."

Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III) by SCHMOLL, Hans-Joachim, CUNNINGHAM, David, SALAZAR, Ramon, BARKER, Peter, MOOKERJEE, Bijoyesh, ROBERTSON, Jane, VAN CUTSEM, Eric, SOBRERO, Alberto, KARAPETIS, Christos S, ROUGIER, Philippe, KOSKI, Sheryl L, KOCAKOVA, Ilona, BONDARENKO, Igor, BODOKY, György, MAINWARING, Paul

“…To compare the efficacy of cediranib (a vascular endothelial growth factor receptor tyrosine kinase inhibitor [VEGFR TKI]) with that of bevacizumab…”
Get full text

Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study by Chen, Eric X, Jonker, Derek J, Loree, Jonathan M, Kennecke, Hagen F, Berry, Scott R, Couture, Felix, Ahmad, Chaudhary E, Goffin, John R, Kavan, Petr, Harb, Mohammed, Colwell, Bruce, Samimi, Setareh, Samson, Benoit, Abbas, Tahir, Aucoin, Nathalie, Aubin, Francine, Koski, Sheryl L, Wei, Alice C, Magoski, Nadine M, Tu, Dongsheng, O'Callaghan, Chris J

“…Single-agent immune checkpoint inhibition has not shown activities in advanced refractory colorectal cancer (CRC), other than in those patients who are…”
Get more information

Immunohistochemical Variation of Human Equilibrative Nucleoside Transporter 1 Protein in Primary Breast Cancers by MACKEY, John R, JENNINGS, Lori L, CASS, Carol E, CLARKE, Marilyn L, SANTOS, Cheryl L, DABBAGH, Laith, VSIANSKA, Michaela, KOSKI, Sheryl L, COUPLAND, Robert W, BALDWIN, Stephen A, YOUNG, James D

“…Gemcitabine and capecitabine are nucleoside analogues used in chemotherapy strategies for the treatment of breast cancer. We previously demonstrated that…”
Get full text

Final Results of a Phase II Clinical Trial of Weekly Docetaxel in Combination with Capecitabine in Anthracycline-Pretreated Metastatic Breast Cancer by Mackey, John R., Tonkin, Katia S., Koski, Sheryl L., Scarfe, Andrew G., Smylie, Michael G.B., Joy, Anil A., Au, Heather-Jane, Bodnar, Dianne M., Soulieres, Denis, Smith, Stephanie W.

“…The addition of capecitabine to docetaxel on a 3-week schedule resulted in superior response rate, increased time to progression (TTP), and improved overall…”
Get full text

Artemin and immune checkpoint inhibitor (ICI) efficacy in metastatic colorectal cancer (mCRC): A correlative analysis of the Canadian Cancer Trials Group (CCTG) CO.26 trial by Ma, Lucy Xiaolu, Titmuss, Emma, Jonker, Derek J., Kennecke, Hagen Fritz, Berry, Scott R., Couture, Felix, Ahmad, Chaudhary E., Goffin, John R., Kavan, Petr, Harb, Mohammed, Colwell, Bruce, Samimi, Setareh, Samson, Benoit, Abbas, Tahir, Aubin, Francine, Koski, Sheryl L., Tu, Dongsheng, O'Callaghan, Christopher J., Loree, Jonathan M., Chen, Eric Xueyu

“…3587 Background: ICIs have limited efficacy in microsatellite stable (MSS) mCRC. The mechanisms of resistance to ICI remain incompletely understood. Recent…”
Get full text

Plasma arginine as a candidate predictive biomarker for response to immune checkpoint inhibition (ICI) in metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial by Ma, Lucy Xiaolu, Loree, Jonathan M., Jonker, Derek J., Kennecke, Hagen Fritz, Berry, Scott R., Couture, Felix, Ahmad, Chaudhary E., Goffin, John R., Kavan, Petr, Harb, Mohammed, Colwell, Bruce, Samimi, Setareh, Samson, Benoit, Abbas, Tahir, Aucoin, Nathalie, Aubin, Francine, Koski, Sheryl L., Tu, Dongsheng, O'Callaghan, Christopher J., Chen, Eric X

“…3545 Background: Nutritional stress is one of the mechanisms used by tumour cells to evade the immune system. Arginine (ARG), an amino acid involved in several…”
Get full text

Plasma phosphocreatine (PC) as a predictive biomarker for immune checkpoint inhibition in patients with refractory metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial by Ma, Lucy Xiaolu, Loree, Jonathan M., Jonker, Derek J., Kennecke, Hagen Fritz, Berry, Scott R., Couture, Felix, Ahmad, Chaudhary E., Goffin, John R., Kavan, Petr, Harb, Mohammed, Colwell, Bruce, Samimi, Setareh, Samson, Benoit, Abbas, Tahir, Aucoin, Nathalie, Aubin, Francine, Koski, Sheryl L., Tu, Dongsheng, O'Callaghan, Christopher J., Chen, Eric Xueyu

“…183 Background: In response to energetic stress, colorectal cancer cells secrete creatine kinase brain-type (CKB). CKB converts creatine and ATP from the…”
Get full text

Effects of liver metastases on efficacy of immune checkpoint blockade in treatment refractory, metastatic colorectal cancer (CRC): CCTG CO.26 by Chen, Eric Xueyu, Loree, Jonathan M., Tu, Dongsheng, O'Callaghan, Christopher J., Kennecke, Hagen Fritz, Jonker, Derek J., Chaudhary, Ahmad, Colwell, Bruce, Harb, Mohammed, Aucoin, Nathalie, Couture, Felix, Samimi, Setareh, Kavan, Petr, Aubin, Francine, Samson, Benoit, Goffin, John R., Berry, Scott, Abbas, Tahir, Koski, Sheryl L., Wei, Alice Chia-chi

“…3600 Background: Immune checkpoint blockade has limited activity in microsatellite-stable (MSS) or mis-match repair proficient (pMMR) CRC. Recent findings…”
Get full text

The CCTG CO.26 trial: A phase II randomized study of durvalumab plustremelimumab and best supportive care (BSC) vs BSC alone in patients with advanced colorectal carcinoma (CRC) refractory to standard therapies by Chen, Eric Xueyu, Jonker, Derek J., Kennecke, Hagen F., Koski, Sheryl L., Wei, Alice Chia-chi, Magoski, Nadine M, Tu, Dongsheng, O'Callaghan, Christopher J.

“…Abstract only TPS3621 Background: Durvalumab (D) is a human monoclonal antibody (mAb) that inhibits binding of programmed cell death ligand 1 (PD-L1) to its…”
Get full text

CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC) by Chen, Eric Xueyu, Jonker, Derek J., Loree, Jonathan M., Kennecke, Hagen F., Berry, Scott R., Couture, Felix, Ahmad, Chaudhary E., Goffin, John R., Kavan, Petr, Harb, Mohammed, Colwell, Bruce, Samimi, Setareh, Samson, Benoit, Abbas, Tahir, Aucoin, Nathalie, Aubin, Francine, Koski, Sheryl L., Wei, Alice Chia-chi, Tu, Dongsheng, O'Callaghan, Christopher J.

“…Abstract only 3512 Background: Targeting both PD-L1 and CTLA-4 may be synergistic immunotherapy approaches. CO.26 evaluated if dual inhibition leads to…”
Get full text

CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC) by Chen, Eric Xueyu, Jonker, Derek J., Kennecke, Hagen F., Berry, Scott R., Couture, Felix, Ahmad, Chaudhary E., Goffin, John R., Kavan, Petr, Harb, Mohammed, Colwell, Bruce, Samimi, Setareh, Samson, Benoit, Abbas, Tahir, Aucoin, Nathalie, Aubin, Francine, Koski, Sheryl L., Wei, Alice Chia-chi, Magoski, Nadine M, Tu, Dongsheng, O'Callaghan, Christopher J.

“…Abstract only 481 Background: D is a human monoclonal antibody (mAb) that inhibits binding of programmed cell death ligand 1 (PD-L1) to its receptor. T is a…”
Get full text

LAPACT: An open-label, multicenter phase II trial of nab -paclitaxel ( nab -P) plus gemcitabine (Gem) in patients (pts) with locally advanced pancreatic cancer (LAPC) by Philip, Philip Agop, Lacy, Jill, Dowden, Scot D., Sastre, Javier, Bathini, Venu Gopal, Cardin, Dana Backlund, Ma, Wen Wee, Sobrero, Alberto F., Koski, Sheryl L., Borg, Christophe, Tonini, Giuseppe, Rivera, Fernando, Hwang, Jimmy J., Knoble, Jeanna L., Al Baghdadi, Tareq, Saif, Wasif M., Meiri, Eyal, Kayitalire, Louis, Li, Jack, Hammel, Pascal

“…Abstract only TPS477 Background: In pts with LAPC, more effective systemic therapies may be associated with improved local control, delay of metastasis, and…”
Get full text

Presentation of a radiation-induced soft-tissue sarcoma interpreted as a breast prosthesis on computed tomographic scan: case report by North, S A, Koski, S L, Campbell, B, Mackey, J R

Get more information